← stocks-llm Find companies like HUMA →

Humacyte, Inc. (HUMA)

Health Care · Tissue engineering and regenerative medicine devices · Nasdaq

Humacyte engineers acellular tissue-based blood vessels (ATEVs) for vascular access and other applications, with its lead product Symvess in late-stage clinical development.

View SEC filings Website Yahoo Finance Find companies like HUMA → Ask about HUMA →

What Humacyte, Inc. does

Humacyte develops acellular tissue engineered vessels (ATEVs) using proprietary technology to create bioengineered blood vessels for vascular applications. The company's lead product, Symvess, is designed to provide an off-the-shelf vascular access solution for hemodialysis patients and is advancing through Phase 3 clinical trials. Humacyte is pursuing FDA and international regulatory approvals and has established a strategic partnership with Fresenius Medical Care for commercialization of its 6-millimeter ATEV in specified markets.

Themes: ["Tissue engineering / regenerative medicine","Vascular access devices","Hemodialysis / renal disease","Bioengineered grafts","Cell-free medical devices"]

Fundamentals

Ask why HUMA looks like this →

Key risks (from latest filing)

["Regulatory approval risk: FDA and EMA approval for Symvess is not guaranteed and may require additional clinical data or design modifications based on ongoing FDA discussions.","Manufacturing scale-up and commercialization risk: Ability to manufacture Symvess in sufficient quantities to meet clinical and commercial demand remains unproven; reliance on third-party manufacturers adds execution risk.","Market adoption and reimbursement uncertainty: Market acceptance, third-party coverage, and reimbursement availability for ATEVs are not assured and could significantly impact commercial viability."]

See HUMA's biggest risks from its latest 10-Q →

Competitors & peers

Not quite? Describe exactly what you want →

Fundamentals: Finnhub, as of 2026-07-13. Filings: SEC EDGAR. Prices are delayed daily-close data.

Last updated 2026-07-10.

Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.